Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795562 | 0.86 | CA1 (0.48) | CCNA2CDK2KDM4ESYKCA1 | |
| SCHEMBL22719004 | 0.86 | KDM4E (0.44) | CCNA2CDK2KDM4ESYKCA1 | |
| SCHEMBL4716419 | 0.86 | LMNA (0.47) | CCNA2CDK2AURKAKDM4ESYK | |
| SCHEMBL22165445 | 0.85 | SYK (0.42) | CCNA2CDK2KDM4ESYKCA1 | |
| SCHEMBL23632985 | 0.82 | MAPT (0.43) | CCNA2CDK2AURKAKDM4ESYK | |
| SCHEMBL4846993 | 0.80 | MAPK1 (0.39) | CCNA2CDK2KDM4ESYKMAPK1 | |
| SCHEMBL30597246 | 0.78 | CCNA2 (0.39) | CCNA2CDK2KDM4ESYKCA1 | |
| SCHEMBL26109252 | 0.78 | CCNA2 (0.39) | CCNA2CDK2KDM4ESYKCA1 | |
| SCHEMBL27519222 | 0.78 | SYK (0.55) | CCNA2CDK2AURKAKDM4ESYK | |
| SCHEMBL14038754 | 0.78 | AURKA (0.45) | AURKAMAPK1MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449581-B2 | 6-Substituted pyrido-pyrimidines | POCHE PALO ALTO LLC (US) | 2008-11-11 | — | — | US | disclosed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY | 2008-06-12 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320987-B2 | 6-Alkoxy-pyrido-pyrimidines | ROCHE PALO ALTO LLC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319102-B1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-15 | — | — | US | disclosed |
| WO-2004014907-A1 | 6-ALKOXY-PYRIDO-PYRIMIDINES AS P-38 MAP KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| EP-1361880-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-19 | — | — | EP | disclosed |
| CN-1451005-A | 7-oxopyridopyrimidines as inhibitors of cell proliferation | HOFFMANN LA ROCHE (CH) | 2003-10-22 | — | — | CN | disclosed |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | SYNTEX (U.S.A.) LLC | 2003-09-11 | — | — | US | disclosed |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | SYNTEX (U.S.A) LLC | 2003-08-14 | — | — | US | disclosed |
| EP-1315726-A1 | 7- OXO PYRIDOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
| WO-2002064594-A2 | 6-SUBSTITUTED PYRIDO-PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002018380-A1 | 7-OXO PYRIDOPYRIMIDINES AS INHIBITORS OF A CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | CCNA2 243/4885CDK2 27/4885AURKA 249/4885 |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | AR, PARP1, DPYD | CCNA2 92/4885CDK2 14/4885AURKA 277/4885 |
| US-20080139588-A1 | Pyrrolo[2,3-d]pyrimidine cytokine inhibitors | DPYD, IL1B, IL6 | CCNA2 1004/4885CDK2 241/4885AURKA 3601/4885 |
| US-20030171584-A1 | Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. | ARRB1, MAPK1, MAPK8 | CCNA2 1885/4885CDK2 789/4885AURKA 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.